Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Brand Name
Curare
Generic Name
Tubocurarine Chloride
Active Ingredient
TubocurarineCategory
Non-Standardized Food Allergenic Extract [EPC]
Salt Form
Chloride
Variants
2
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Curare, you must consult a qualified healthcare professional.
Detailed information about Curare
Tubocurarine Chloride is a non-depolarizing neuromuscular blocking agent used to induce skeletal muscle relaxation during surgery and mechanical ventilation. It belongs to the isoquinoline class of neuromuscular blockers.
Dosage of Tubocurarine must be strictly individualized based on the patient's weight, age, physical status, and the specific requirements of the surgical procedure. Because of the risk of profound respiratory depression, all doses are administered by an anesthesiologist or CRNA.
Tubocurarine has been used in pediatric populations, but extreme caution is required due to the sensitivity of infants to non-depolarizing agents.
Since the kidneys are the primary route of elimination for Tubocurarine, patients with renal failure (GFR < 30 mL/min) will experience a significantly prolonged duration of action. Doses should be reduced by 25% to 50%, and maintenance doses should be spaced further apart. Continuous monitoring with a nerve stimulator is mandatory.
While metabolism is minimal, hepatic impairment can affect the volume of distribution and biliary clearance. In patients with cirrhosis, a higher initial dose may be needed due to an increased volume of distribution, but the subsequent elimination half-life may be prolonged, leading to a risk of 'recurarization' (return of paralysis after apparent recovery).
Geriatric patients often have reduced renal clearance and a higher prevalence of cardiovascular disease. Lower initial doses and slower titration are recommended to avoid prolonged paralysis and severe hypotension.
Tubocurarine is never self-administered. It is given exclusively via intravenous injection by a medical professional.
As Tubocurarine is administered only in a controlled clinical environment for specific procedures, the concept of a 'missed dose' by a patient does not apply. If a maintenance dose is delayed during surgery, the anesthesia provider will observe a return of muscle twitching or patient movement and will adjust the administration immediately.
An overdose of Tubocurarine leads to prolonged and profound muscle paralysis, including the diaphragm and intercostal muscles, resulting in respiratory arrest.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance. This drug is for hospital use only.
The most significant and common side effects of Tubocurarine are related to its ability to trigger the release of endogenous histamine from mast cells and its secondary effects on the autonomic nervous system.
Tubocurarine is a potent neuromuscular paralytic. It does not provide any sedation, analgesia (pain relief), or amnesia. A patient paralyzed with Tubocurarine is fully awake and can feel pain but is unable to move or cry out. Therefore, it MUST always be administered in conjunction with adequate general anesthesia or sedation.
No FDA black box warnings for Tubocurarine. However, the FDA-approved labeling emphasizes that this drug should only be administered by clinicians experienced in the use of neuromuscular blocking agents and in the management of the complications that may arise from their use.
Tubocurarine must NEVER be used in the following circumstances:
Conditions requiring careful risk-benefit analysis include:
Tubocurarine is classified as FDA Pregnancy Category C. Animal reproduction studies have not been conducted, and it is not known whether Tubocurarine can cause fetal harm when administered to a pregnant woman.
It is not known whether Tubocurarine is excreted in human milk. However, because the drug is not absorbed orally, any drug present in the milk would be unlikely to affect the nursing infant. Regardless, caution should be exercised, and breastfeeding is usually deferred for at least 24 hours post-anesthesia to allow for the clearance of all anesthetic agents.
Tubocurarine is a classic non-depolarizing neuromuscular blocking agent. It acts as a competitive antagonist at the nicotinic acetylcholine receptors (nAChR) located on the motor endplate of skeletal muscle. By binding to one or both of the alpha subunits of the receptor, it prevents the endogenous neurotransmitter, acetylcholine, from binding and initiating the opening of the ion channel. This prevents the influx of sodium ions and the efflux of potassium ions, thereby preventing the endplate potential from reaching the threshold required to trigger an action potential in the muscle fiber. The result is a complete cessation of voluntary and involuntary skeletal muscle contraction.
Common questions about Curare
Tubocurarine is primarily used during major surgery to paralyze skeletal muscles, which prevents involuntary movement and makes it easier for surgeons to operate on areas like the abdomen. It is also used to help doctors insert a breathing tube (endotracheal intubation) and to assist patients who are on a mechanical ventilator in the intensive care unit. Because it stops the muscles used for breathing, it must only be used when a machine is available to breathe for the patient. It is an adjunct to general anesthesia, meaning it is used alongside drugs that make the patient unconscious. It does not relieve pain or cause sleep on its own.
The most common side effects of Tubocurarine are a drop in blood pressure (hypotension) and an increased heart rate (tachycardia). These effects happen because the drug causes the body to release histamine, which widens blood vessels, and because it interferes with certain nerve signals that control the heart. Patients may also experience skin flushing or redness, particularly on the upper body. In some cases, it can cause wheezing or breathing difficulties (bronchospasm), especially in people with asthma. Because it is given during surgery, the medical team monitors these effects constantly and treats them immediately with fluids or other medications.
You cannot drink alcohol while Tubocurarine is in your system, and you should avoid alcohol for at least 24 hours after your surgery. Alcohol can significantly increase the effects of the other anesthetic drugs you received alongside Tubocurarine, which could lead to dangerous levels of drowsiness or breathing problems. Furthermore, alcohol can interfere with your body's ability to fully recover its muscle strength. Always wait until your doctor confirms that the anesthesia has completely worn off and your vital signs are stable before consuming any alcoholic beverages. Your safety in the recovery period depends on your body clearing these potent medications without interference.
Tubocurarine is generally avoided during pregnancy unless the potential benefits outweigh the risks, as it is classified as Pregnancy Category C. While the drug does not easily cross the placenta to reach the baby, it can cause the mother's blood pressure to drop significantly, which might reduce the amount of oxygen reaching the fetus. If it is used during a Cesarean section, the medical team will carefully monitor the newborn for any signs of muscle weakness or trouble breathing. Most doctors today prefer newer, shorter-acting muscle relaxants for pregnant patients. Always discuss the risks of anesthesia with your obstetrician and anesthesiologist if you are pregnant.
When injected into a vein, Tubocurarine typically begins to work within 3 to 5 minutes. You will first notice weakness in small muscles like those in the eyes and fingers, followed by the limbs, and finally the muscles used for breathing. Because it takes several minutes to reach its full effect, it is considered a 'slow-onset' muscle relaxant compared to some newer drugs. The effects usually last between 60 to 90 minutes, though this can be much longer in people with kidney or liver problems. The anesthesiologist will use a special nerve stimulator to check exactly how much the drug is still affecting your muscles throughout the procedure.
Tubocurarine is not a medication that you take on a regular schedule; it is a one-time or short-term treatment given only during a medical procedure. Therefore, there is no way for a patient to 'stop' taking it. Once the surgery is over, the drug naturally wears off as your body eliminates it through your kidneys. If the drug is still working when the surgery ends, the anesthesiologist will give you a 'reversal agent' like neostigmine to quickly wake up your muscles. You will stay in a recovery room until the medical staff is certain that your muscle strength has fully returned and you can breathe safely on your own.
It is impossible for a patient to miss a dose of Tubocurarine because it is only administered by healthcare professionals in a hospital setting. The anesthesiologist calculates the exact amount you need and gives it to you through an IV line during your surgery. If more is needed to keep your muscles relaxed, they will provide additional doses based on real-time monitoring of your muscle responses. You do not need to worry about a dosing schedule or remembering to take this medication yourself. All aspects of the administration are handled by the surgical and anesthesia team.
No, Tubocurarine does not cause weight gain. It is a short-acting medication used only during surgery or in emergency medical situations. It does not affect your metabolism, appetite, or fat storage in a way that would lead to weight changes. Any weight changes you might notice after a surgery are more likely due to IV fluids given during the procedure, changes in your diet during recovery, or the physical stress of the surgery itself. If you have concerns about weight gain after a hospital stay, you should discuss them with your primary care physician or surgeon.
Tubocurarine has many significant interactions with other drugs, which is why your anesthesiologist must know your full medical history. Certain antibiotics (like gentamicin), heart medications (like quinidine), and even some diuretics can make Tubocurarine much stronger or cause it to last much longer than expected. This can be dangerous if it prevents you from breathing on your own after surgery. Conversely, some medications might make it less effective. Your medical team is trained to adjust the dose of Tubocurarine based on the other medications you are taking to ensure your safety during and after the procedure.
Yes, Tubocurarine Chloride is available as a generic medication. However, because it is an older drug that has been largely replaced by newer muscle relaxants with fewer side effects, it is not as commonly stocked in hospitals as it once was. You will not find it at a retail pharmacy, as it is strictly for use in hospitals and surgical centers. Even as a generic, it must only be handled by specialists. If your surgery requires a muscle relaxant, your anesthesiologist will choose the specific brand or generic agent that is safest and most effective for your individual needs.
> Warning: Stop taking Tubocurarine and call your doctor immediately if you experience any of these. (Note: Since this is administered in a hospital, the medical team will respond immediately).
Tubocurarine is intended for acute, short-term use. However, prolonged use in the ICU setting has been associated with:
There is no specific FDA 'Black Box Warning' for Tubocurarine in the modern format, as it predates the current system. However, its labeling carries the equivalent of a 'strong warning' regarding its potential for fatal respiratory paralysis. It must only be used by clinicians who are experts in airway management and where facilities for intubation and mechanical ventilation are immediately available.
Report any unusual symptoms to your healthcare provider. In the post-operative period, inform your nurse if you feel exceptionally weak or have difficulty swallowing.
Patients should not drive or operate heavy machinery for at least 24 hours after receiving Tubocurarine, as residual muscle weakness and the effects of accompanying anesthesia can impair physical and mental coordination.
Alcohol should be avoided for at least 24 hours following the administration of Tubocurarine. Alcohol can potentiate the CNS depressant effects of the anesthetics used alongside Tubocurarine and may interfere with the recovery of normal neuromuscular function.
As an acute-use medication, there is no tapering requirement. However, the medical team must ensure 'full reversal' (a TOF ratio > 0.9) before the patient is allowed to breathe entirely on their own and is moved to a recovery room.
> Important: Discuss all your medical conditions with your healthcare provider before starting Tubocurarine. Ensure they are aware of any history of neuromuscular disorders or severe allergies.
There are no known direct food interactions with Tubocurarine, as the drug is administered intravenously and is not absorbed through the gut. However, the patient's nutritional status (specifically protein levels) can affect drug binding and distribution.
Tubocurarine is not known to significantly interfere with standard laboratory blood tests. However, its physiological effects (like histamine release) may cause transient changes in white blood cell counts or plasma histamine levels if measured immediately after administration.
For each major interaction, the mechanism involves either a pharmacodynamic synergy (acting on the same receptor or pathway) or a pharmacokinetic alteration (changing how the drug is cleared). The clinical consequence is almost always an increased risk of prolonged paralysis and respiratory arrest.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially any antibiotics or heart medications.
There is evidence of cross-reactivity between various neuromuscular blocking agents. The quaternary ammonium groups found in Tubocurarine are also present in many other drugs, detergents, and even some foods. Patients who have had an unexplained reaction during a previous surgery should undergo skin testing or specialized IgE testing before receiving Tubocurarine.
> Important: Your healthcare provider will evaluate your complete medical history, including any previous experiences with anesthesia, before prescribing Tubocurarine.
As noted in the dosage section, pediatric patients, especially neonates, exhibit altered sensitivity to Tubocurarine. The neuromuscular junction is not fully mature at birth, leading to unpredictable responses. While it is approved for use in children, it is rarely the first choice in modern pediatric anesthesia due to the availability of agents with faster onset and fewer cardiovascular effects.
Elderly patients (over 65) are at increased risk for complications from Tubocurarine.
In patients with renal failure, the plasma clearance of Tubocurarine is reduced by approximately 40% to 50%. This leads to a significant increase in the elimination half-life. If Tubocurarine must be used, the dose must be reduced, and the patient must be monitored closely for 'residual curarization' in the recovery room.
In patients with liver disease, the volume of distribution may be increased due to changes in plasma proteins and fluid shifts (ascites). This may necessitate a larger initial dose to achieve paralysis, but the subsequent recovery may be delayed due to impaired biliary excretion and altered metabolism.
> Important: Special populations require individualized medical assessment. Always inform your anesthesiologist if you are pregnant, nursing, or have kidney or liver disease.
| Parameter | Value |
|---|---|
| Bioavailability | 0% (Oral), 100% (IV) |
| Protein Binding | 40% - 50% |
| Half-life | ~2 hours |
| Tmax | Immediate (IV) |
| Metabolism | Minimal (Hepatic) |
| Excretion | Renal 40-60%, Biliary 10-20% |
Tubocurarine is the parent compound of the non-depolarizing neuromuscular blocker class. It is specifically an isoquinoline derivative. Related medications include Atracurium, Cisatracurium, and Mivacurium, all of which were designed to minimize the histamine release and ganglionic blockade associated with Tubocurarine.